Insmed (NASDAQ:INSM) Downgraded by Zacks Investment Research to Sell
According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. “
Other analysts have also recently issued research reports about the company. BidaskClub cut Insmed from a buy rating to a hold rating in a report on Friday, January 1st. Morgan Stanley raised their price target on Insmed from $42.00 to $55.00 and gave the company an overweight rating in a report on Wednesday, December 16th. Stifel Nicolaus started coverage on Insmed in a report on Monday, October 12th. They issued a buy rating and a $44.00 price target on the stock. SVB Leerink raised their price target on Insmed from $51.00 to $55.00 and gave the company an outperform rating in a report on Monday, January 4th. Finally, Berenberg Bank started coverage on Insmed in a report on Thursday, December 17th. They issued a buy rating and a $48.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. Insmed currently has a consensus rating of Buy and a consensus price target of $47.40.
Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.04). The company had revenue of $43.64 million for the quarter, compared to analysts’ expectations of $46.07 million. Insmed had a negative return on equity of 79.58% and a negative net margin of 145.14%. The business’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same period last year, the company posted ($0.68) EPS. As a group, equities analysts expect that Insmed will post -2.58 EPS for the current fiscal year.
In other news, CEO William Lewis sold 200,000 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $34.03, for a total transaction of $6,806,000.00. Following the transaction, the chief executive officer now directly owns 129,787 shares in the company, valued at approximately $4,416,651.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christine A. Pellizzari sold 30,000 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $34.28, for a total value of $1,028,400.00. Following the transaction, the insider now owns 94,348 shares in the company, valued at $3,234,249.44. The disclosure for this sale can be found here. Insiders have sold a total of 250,000 shares of company stock worth $8,625,800 over the last quarter. Corporate insiders own 4.63% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. William Blair Investment Management LLC lifted its stake in shares of Insmed by 191.3% in the 3rd quarter. William Blair Investment Management LLC now owns 2,386,996 shares of the biopharmaceutical company’s stock valued at $76,718,000 after purchasing an additional 1,567,605 shares during the period. FMR LLC lifted its stake in shares of Insmed by 10.9% in the 2nd quarter. FMR LLC now owns 14,933,881 shares of the biopharmaceutical company’s stock valued at $411,279,000 after purchasing an additional 1,467,747 shares during the period. Lord Abbett & CO. LLC lifted its stake in shares of Insmed by 498.6% in the 3rd quarter. Lord Abbett & CO. LLC now owns 1,347,464 shares of the biopharmaceutical company’s stock valued at $43,308,000 after purchasing an additional 1,122,357 shares during the period. Vanguard Group Inc. lifted its stake in shares of Insmed by 11.4% in the 2nd quarter. Vanguard Group Inc. now owns 9,396,749 shares of the biopharmaceutical company’s stock valued at $258,786,000 after purchasing an additional 959,588 shares during the period. Finally, Polar Capital LLP lifted its stake in shares of Insmed by 65.8% in the 3rd quarter. Polar Capital LLP now owns 763,376 shares of the biopharmaceutical company’s stock valued at $24,535,000 after purchasing an additional 303,026 shares during the period.
Insmed Company Profile
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.